demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 prophylaxis (excluding children)
cilgavimab and tixagevimab (Evusheld) PROVENT

3 studies excluded by filtering options 0

6672 TACKLE, 0 110risk of bias not avaialble
9866 Jurdi, 2022 1110not a RCTrisk of bias not avaialble
10191 Chen, 2022 0100selection pending